Skip to main content
Sonnet BioTherapeutics Holdings, Inc. logo

Sonnet BioTherapeutics Holdings, Inc. — Investor Relations & Filings

Ticker · SONN ISIN · US83548R1059 US Manufacturing
Filings indexed 1,051 across all filing types
Latest filing 2025-12-17 Regulatory Filings
Country US United States of America
Listing US SONN

About Sonnet BioTherapeutics Holdings, Inc.

https://www.sonnetbio.com/

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company that develops innovative biologic medicines, primarily for oncology. The company's proprietary Fully Human Albumin Binding (FHAB) platform is designed to improve the therapeutic properties of cytokines and other biologics. The FHAB technology utilizes a single-chain antibody fragment that binds to human serum albumin, enabling targeted delivery of therapeutic payloads directly to tumor tissue. This approach aims to enhance drug penetration, retention, and local activation within the tumor microenvironment, potentially increasing efficacy while minimizing systemic toxicity. Sonnet's pipeline includes several cytokine-derived therapeutic candidates in various stages of clinical development.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.